Hedeker Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Hedeker Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.41M	Buy	7,626 +2,961	+63%	+$1.38M	0.72%	42
2025 Q4	$2.11M	Sell	4,665 -2,996	-39%	-$1.29M	0.44%	54
2025 Q3	$3M	Sell	7,661 -1,130	-13%	-$472K	0.62%	46
2025 Q2	$3.91M	Sell	8,791 -216	-2%	-$99.5K	0.91%	37
2025 Q1	$4.37M	Buy	+9,007	New	+$4.2M	1.17%	31
2021 Q3	–	Sell	-8,717	Closed	-$1.76M	–	94
2021 Q2	$1.76M	Buy	8,717 +122	+1%	+$25.5K	0.55%	60
2021 Q1	$1.85M	Buy	8,595 +202	+2%	+$44.4K	0.65%	55
2020 Q4	$1.98M	Buy	8,393 +706	+9%	+$162K	0.69%	55
2020 Q3	$2.09M	Buy	+7,687	New	+$2.12M	0.99%	45

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Hedeker Wealth's VRTX Position: Q1 2026 in Review

Hedeker Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 63% in Q1 2026, buying an estimated $1.38M and bringing the position to 7,626 shares worth $3.41M. The position accounts for 0.72% of the portfolio, ranked #42.

Hedeker Wealth first reported a position in VRTX in Q3 2020 and has held it in 9 quarters since. The position peaked at $4.37M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Hedeker Wealth held 7,626 shares of Vertex Pharmaceuticals worth $3.41M as of Q1 2026.
Hedeker Wealth bought 2,961 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.38M.
Vertex Pharmaceuticals made up 0.72% of Hedeker Wealth's portfolio in Q1 2026, its #42 holding.
Hedeker Wealth first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 9 quarters since.
Hedeker Wealth's Vertex Pharmaceuticals position peaked at $4.37M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Hedeker Wealth's 13F filing for Q1 2026, filed 11 May 2026.